Steven Mah
Stock Analyst at TD Cowen
(2.23)
# 2,812
Out of 5,242 analysts
29
Total ratings
37.93%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $53.66 | +8.09% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $24.00 | +29.17% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.72 | +1,454.40% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $2.96 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $12.32 | +240.91% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $4.57 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $2.58 | +287.60% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $4.95 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.58 | +713.95% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $204.92 | -24.36% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $16.41 | +753.14% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.19 | +4,269.75% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $141.92 | +192.42% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $11.91 | +1,999.08% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $53.66
Upside: +8.09%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $24.00
Upside: +29.17%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.72
Upside: +1,454.40%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $2.96
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $12.32
Upside: +240.91%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.57
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $2.58
Upside: +287.60%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.95
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.58
Upside: +713.95%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $204.92
Upside: -24.36%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $16.41
Upside: +753.14%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.19
Upside: +4,269.75%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $141.92
Upside: +192.42%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $11.91
Upside: +1,999.08%